GlassScriptPhysician profile
John P Feltz
NPI 1619928934
$1,602.81
in general payments reported to CMS, 2019-2025
30 companies · $515 in 2025
The $515 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $52.35 · 2021: $225 · 2022: $122 · 2023: $205 · 2024: $106 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.85 |
| Education | $334.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $357.76 | 2025 | Veozah |
| Applied Medical Resources Corporation | $197.35 | 2021 | |
| Abbvie INC. | $117.38 | 2019-2023 | |
| Hologic Sales and Service, LLC | $94.15 | 2019-2024 | Aptima, Novasure, Myosure Tissue Removal Device |
| Medtronic, INC. | $84.97 | 2025 | Truclear |
| Mayne Pharma Commercial LLC | $79.63 | 2022-2023 | |
| Medline Industries LP | $70.37 | 2019 | |
| Avion Pharmaceuticals | $56.11 | 2019-2021 | |
| Exact Sciences Corporation | $45.89 | 2025 | The Cologuard Plus Collection Kit |
| Channel Medsystems, INC. | $43.51 | 2023 | |
| Daiichi Sankyo INC. | $42.78 | 2019-2020 | |
| Allergan, INC. | $42.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.27 | 2019-2023 | |
| Olympus America INC. | $39.50 | 2019-2023 | Endoeye Flex 3d Deflectable Videoscope |
| Sumitomo Pharma America, INC. | $37.40 | 2023-2024 | Myfembree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dysis Medical, INC. | $33.47 | 2021-2022 | |
| Therapeuticsmd, INC. | $28.07 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $27.00 | 2019 | |
| Organon LLC | $26.85 | 2023-2025 | Nexplanon |
| Sanofi Pasteur INC. | $15.24 | 2025 | |
| Glaxosmithkline, LLC. | $14.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.91 | 2022 | |
| Minerva Surgical, INC | $14.26 | 2019 | |
| Covidien LP | $14.05 | 2019 | |
| Celularity INC. | $14.00 | 2019 | |
| Pfizer INC. | $13.58 | 2024 | |
| Myovant Sciences INC. | $12.86 | 2022 | |
| Roche Diagnostics Corporation | $12.84 | 2019 | |
| Exeltis, USA INC. | $11.54 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.